Geron Corporation reported $60.1 million in net product revenue for Q3 2026, a 5% increase from Q2, driven by growing demand for its blood cancer drug RYTELO in the U.S. The company initiated a phased commercial launch in Europe, targeting Germany by year-end, to expand access for eligible patients. Geron also improved its 2026 financial guidance by lowering total operating expenses to $220-$230 million while maintaining revenue expectations of $220-$240 million. With $339 million in cash and equivalents, Geron is positioned to fund operations and pursue growth opportunities in hematology.
Geron Corporation's Q3 2026 financial results show $60.1 million in net product revenue, reflecting growth in its blood cancer drug sales and a new European launch. For readers following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 18:41 WIB: out of 150 priced US health stocks, 118 rose and 24 fell today. Notable movers include CGC at USD 0.75 (+6.13%, 0% Sell / 100% Buy, typical hold 40 days), TLRY at USD 2.81 (+6.04%, 96% Sell / 4% Buy, typical hold 32 days), and INO at USD 1.76 (+6.02%, 53% Sell / 47% Buy, typical hold 41 days).
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
